TC Biopharm Holdings PLC

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

3 Patients Dosed in 5 Patient Safety Cohort EDINBURGH, Scotland , Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML). The initial 5 patients in the trial are deemed a "safety cohort", spaced two weeks apart with safety review by an oversight board to confirm no drug related toxicity issues, subsequent to 5 patients being dosed the study will advance to open enrollment.

TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia

SAB selected to advance new therapeutic trials and strategic partnerships EDINBURGH, Scotland , Oct. 26, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced the company has completed its scientific advisory board (SAB) to advance new therapeutic trials and establish strategic relationships within the cell therapy sector. "I appreciate the esteemed members of the SAB joining myself and TCBP in our efforts in building this innovative cell therapy development company," said Bryan Kobel, Chief Executive Officer.

TC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy Expertise

EDINBURGH, Scotland , Oct. 3, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that management will be presenting at the Dawson James 7th Annual Small Cap Growth Conference and LD MICRO Main Event XV. TC BioPharm management will host one-on-one meetings with institutional investors at these conferences.

TC BioPharm to Present at Upcoming Investor Conferences

EDINBURGH, Scotland , Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced that it has received approval from the UK regulatory body MHRA to apply an 18-month extrapolated shelf life to its current allogeneic cell therapy product, OmnImmune®.

TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®

EDINBURGH, Scotland , Aug. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Chief Executive Officer, Bryan Kobel will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, on Monday, September 12th at 7:00 am.

TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Event Taking Place in Boston on July 26-28, 2022 EDINBURGH, Scotland , July 25, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that several key executives will speak at The 3rd Gamma Delta T Therapies Summit, which will take place on July 26-28, 2022 in Boston, MA. TC BioPharm will participate in five separate conference sessions Emilio Cosimo , Product Development Manager, will participate in a workshop, "Characterizing Gamma Delta Subsets to Interrogate Function & Therapeutic Application," on July 26, 2022 at 11am EDT.

TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit

Management will Participate in Fireside Chat on TC BioPharm's Journey as a Successful CGT Startup on July 13, 2022 EDINBURGH, Scotland., July 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, today announced that Bryan Kobel, CEO, will be speaking at the "Innovating Cell and Gene Therapy Quality Control Conference 2022.

TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"

EDINBURGH, Scotland , June 7, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer indications, today announced the closing of its previously announced underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting discounts and commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1.5 million ADSs at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

TC Biopharm Announces Closing of $4 Million Underwritten Public Offering

EDINBURGH, Scotland , June 2, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of an underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting discounts and commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 ADSs at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering

EDINBURGH, Scotland , May 31, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Acute myeloid leukemia (AML) diagnoses have risen globally according to a recent study entitled, "EPR22-104: A Comparison of the Burden of Leukemia Amongst Various Regions of the World, 1990-2019," published in the Journal of the National Comprehensive Cancer Network. The authors analyzed data from the World Health Organization from 1990 to 2019 and found that AML incidences grew by 34.6% among men and grew by 7.9% among women.

TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally

Sector is Expected to Surpass $4 Billion by 2028 Report Highlights Promising Therapy and Rising Investment from Pharmaceutical Companies EDINBURGH, Scotland , May 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Kuick Research has recognized the Company as a key player in the gamma-delta T cell therapy market.  In April, Kuick Research released its "Gamma Delta T Cell Cancer Therapy Market and Clinical Trials Forecast 2028" which focuses on the therapy, the companies in the sector, updates on the current drugs in research & development, and the size of the sector.

Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market

Dr. Mark Bonyhadi to spearhead SAB EDINBURGH, Scotland, May 18, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today announced the formation of a scientific advisory board (SAB) to advance its gamma-delta T cell therapy, OmnImmune®, for the treatment of Acute Myeloid Leukemia (AML). "We are honored to have these remarkable and accomplished cell therapeutics and scientific leaders join TC BioPharm's Scientific Advisory Board," said Bryan Kobel, CEO of TC BioPharm.

TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts

EDINBURGH, Scotland , May 3, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that the company will participate at the upcoming 2022 LD Micro Invitational, a prominent 3-day investor conference, at the Four Seasons Hotel Westlake Village on June 7th-9th, 2022. The LD Micro Conference will host approximately 200 companies from all over the world.

TC BioPharm Invited to Present at LD Micro Conference

EDINBURGH, Scotland , April 26, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that the company will be participating in several upcoming conferences. TC BioPharm Co-founder and Executive Chariman, Michael Leek will participate in the Allogeneic Cell Therapies Summit , at the Hilton Boston Northshore between 9-11 May, 2022.

TC BioPharm to Participate in Upcoming Conferences

EDINBURGH, Scotland , April 21, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that it has made a donation to the Leukemia and Lymphoma Society in order to help bring awareness to World AML Day. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow.

TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML Day

6-month shelf-life milestone achieved Successful thaw of highly activated Gamma delta cells EDINBURGH, Scotland , April 6, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that it has successfully registered the UK trademark "CryoTC®", for the Company's proprietary process for freezing and thawing of its lead oncology product, OmnImmune®. CryoTR® is TC BioPharm's unique process of cryopreservation, which is performed in a controlled rate freezer using an optimized protocol.

TC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing Process

EDINBURGH, Scotland , March 29, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that is has received fundamental research coverage from EF Hutton, with a "Buy" opinion rating and a target price of $5. The EF Hutton coverage initiation follows TC BioPharm achieving two important recent corporate milestones: Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells Announcing  orphan drug status had been granted for lead product OmnImmune® for use in Acute Myeloid Leukemia ("AML") All reports on EF Hutton  prepared by analysts represent the views of those analysts and are not necessarily those of TC BioPharm.

TC BioPharm Announces Initiation of Equity Analyst Coverage by EF Hutton with a "Buy" Recommendation

Trial enrollment expected to begin during the first half of 2022 EDINBURGH, Scotland , March 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced that it has received MHRA and Research Ethics Committee approvals to initiate gamma-delta T cell therapy clinical trials of OmnImmune® for the treatment of Acute Myeloid Leukemia (AML). OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells has already received orphan drug designation for the treatment of patients suffering from the blood and bone marrow cancer.

TC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Treatment of Acute Myeloid Leukemia

The FDA has granted Orphan Drug designation to TC Biopharm Ltd's (NASDAQ: TCBP) lead product OmnImmune for use in Acute Myeloid Leukemia.  After reviewing the Phase 1b/2a trial results in relapsed/refractory AML patients, the FDA approved the Company's application.

Why Are TC Biopharm Shares Trading Higher Today

Allogeneic unmodified Gamma Delta product can be stored frozen and used as an 'off-the-shelf' cell therapy EDINBURGH, Scotland , March 17, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announces orphan drug status has been granted for lead product OmnImmune® for use in Acute Myeloid Leukemia ("AML"). After reviewing the Phase 1b/2a trial results in relapse/refractory AML patients the FDA approved the Company's application for Orphan Drug Status.

TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune®

EDINBURGH, Scotland, March 15, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, today highlighted their intellectual property TC BioPharm's boasts a strong IP portfolio of patents covering manufacturing and commercialization of GD-T cell products and their modification via CAR-T. Currently The Company owns 6 granted patents and a further 45 patent applications in 6 families encompassing: allogeneic gamma-delta T cells; novel 'co-stimulatory' gamma-delta CAR-T cells intended to mitigate on-target, off-tumour toxicity and broaden the choice of therapeutic targets addressable by CAR-T therapies; novel CAR constructs tailored for use in gamma-delta T-cells; modified gamma-delta T-cells intended to maintain activity in the immune suppressive solid tumour microenvironment; and proprietary antigen binders,and have an exclusive license to an additional 1 family of 3 granted patent application and 11 patent applications in the area of 'co-stimulatory' gamma-delta CAR-T cells.

TC Biopharm Updates Intellectual Property Portfolio

TC Biopharm Ltd (NASDAQ: TCBP) has announced interim data from Phase 1a/2b of TCB-002, OmnImmune in relapsed/refractory Acute Myeloid Leukemia (AML).  TCB-002 is the Company's allogeneic unmodified gamma delta t-cell product.

Newly-Listed TC Biopharm Highlights Early Data From Acute Myeloid Leukemia Trial

EDINBURGH, Scotland, March 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announces positive interim data its Phase 1a/2b human study evaluating safety and tolerability of TCB-002, OmnImmune®, the Company's allogeneic unmodified gamma delta t-cell product, a novel therapeutic targeting the potential treatment of relapse/refractory Acute Myeloid Leukemia ("AML").  7 patients received treatment and 2 patients (enrolled in the low dose cohort) did not reach day 28 assessment and were not evaluable for efficacy per protocol with the third patient being available for safety inclusion but not efficacy.

TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

EDINBURGH, Scotland, March 2, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that it will host a corporate update call for interested parties on Tuesday, March  8, 2022 at 9:00 am ET. The event will be available via the investor relations section of the company's website.

TC Biopharm to Host Corporate Update Call on March 8th

EDINBURGH, Scotland, Feb. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, is pleased to announce the appointment of 4 new members to its Board of Directors. Joining the board are Mark Bonyhadi, James Culverwell, Arlene Morris and Edward Niemczyk.

News for TC Biopharm Holdings PLC Stock (TCBP)